[SYS_OK] MEA_0 ACTIVE -- 862 Hz mean spike rate -- donor 924A consent verified -- 37.0 C -- rack draw 914 W -- 0.85 Gop/W -- MEA_1 ACTIVE -- 743 Hz -- donor 482B consent verified -- 37.1 C -- perfusion nominal --
OrganoidBiofoundry
Drug discovery · PDOs

Patient-derived tumor organoids

A patient-derived organoid is a three-dimensional culture grown from a patient's own tumor that keeps the tumor's genetics and behavior, so a drug can be tested on the disease itself rather than on a generic cell line.

The promise is precise: test the drugs on the tumor before giving them to the person. In gastrointestinal cancers, organoid response has correlated with how patients actually responded in the clinic, which is the result that moved patient-derived organoids from interesting to useful.18

How a PDO is made and validated

A tumor biopsy or resection is dissociated and grown in a matrix gel with the growth factors that tumor type needs, forming organoids within weeks. The crucial step is validation: before any drug test means anything, the organoid is checked against the source tumor by genomic sequencing and histology to confirm it still carries the same driver mutations and looks like the original tissue. A PDO that has drifted from its parent tumor is worse than useless, because it looks like a real answer.

From biopsy to pharmacotyping A pipeline from a patient biopsy through organoid culture, genomic and histological validation against the source tumor, drug-panel testing, and a per-patient response profile. Biopsy / resection patient tumor Organoid culture matrix + factors Validate genomics + histology Drug panel pharmacotyping Response profile per patient
A biopsy becomes a validated organoid line, then a per-patient drug-response profile. Validation against the source tumor is the step that makes the rest trustworthy.

Pharmacotyping: matching drugs to a tumor

Once validated, a PDO line is exposed to a panel of drugs across concentrations, and its dose-response is read by viability imaging and metabolic sensors. The output is a per-patient sensitivity profile, a ranking of which compounds the tumor responds to. Built into living biobanks across many patients, these profiles also let researchers ask which molecular features predict response, turning individual results into transferable knowledge.19 The harder tumors, where stroma or heterogeneity defeats this simple approach, are covered under PDAC and glioblastoma.

Frequently asked questions

What is a patient-derived organoid?

A 3D culture grown from a patient's own tumor that retains the tumor's genetics and behavior, used to predict how that patient's cancer will respond to drugs.

Do PDO results actually predict patient response?

In several cancer types, notably gastrointestinal cancers, organoid drug responses have correlated with clinical outcomes, though predictive accuracy varies by tumor type and is still being established.

Why is validation against the source tumor so important?

Because an organoid that has genetically drifted from its parent tumor gives misleading results. Genomic and histological checks confirm the model still represents the patient's actual disease.

References

  1. Vlachogiannis G, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359(6378):920-926. doi:10.1126/science.aao2774. Accessed 2026-06-12.
  2. Drost J, Clevers H. Organoids in cancer research. Nature Reviews Cancer. 2018;18(7):407-418. doi:10.1038/s41568-018-0007-6. Accessed 2026-06-12.